Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses

A. Choudhury, J. C. Liang, E. K. Thomas, L. Flores-Romo, O. S. Xie, K. Agusala, S. Sutaria, I. Sinha, R. E. Champlin, David Claxton

Research output: Contribution to journalArticle

225 Citations (Scopus)

Abstract

We have previously reported that leukemic dendritic cells (DC) can be generated ex vivo from myelomonocytic precursors in chronic myelogenous leukemia. In this study we report the generation of DC from acute mye1ogenous leukemia (AML) cells and their potent ability to stimulate leukemia-specific cytolytic activity in autologous lymphocytes. DC were generated in vitro using granulocyte-macrophage colony-stimulating factor+interleukin-4 in combination with either tumor necrosis factor-α or CD40 ligand (CD40L). Cells from 19 AML patients with a variety of chromosomal abnormalities were studied for their ability to generate DC. In all but 1 case, cells with the morphology, phenotypic characteristics, and T-cell stimulatory properties of DC could be generated. These cells expressed high levels of major histocompatibility complex class I and class II antigens as well as the costimulatory molecules B7-2 and ICAM-1. In three cases these cells were determined to be of leukemic origin by fluorescence in situ hybridization for chromosomal abnormalities or Western blotting for the inv(16) fusion gene product. Autologous lymphocytes cocultured with AML-derived DC (DC-AL) were able to lyse autologous leukemia targets, whereas little cytotoxicity was noted against autologous, normal cells obtained from the patients during remission. We conclude that leukemia derived DC may be useful for immunotherapy of many AML patients.

Original languageEnglish (US)
Pages (from-to)780-786
Number of pages7
JournalBlood
Volume93
Issue number3
StatePublished - Feb 1 1999

Fingerprint

T-cells
Acute Myeloid Leukemia
Dendritic Cells
Leukemia
T-Lymphocytes
Lymphocytes
Chromosome Aberrations
CD86 Antigens
CD40 Ligand
In Vitro Techniques
Gene Fusion
Histocompatibility Antigens Class II
Intercellular Adhesion Molecule-1
Granulocyte-Macrophage Colony-Stimulating Factor
Cytotoxicity
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Major Histocompatibility Complex
Fluorescence In Situ Hybridization
Interleukin-4
Immunotherapy

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Choudhury, A., Liang, J. C., Thomas, E. K., Flores-Romo, L., Xie, O. S., Agusala, K., ... Claxton, D. (1999). Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood, 93(3), 780-786.
Choudhury, A. ; Liang, J. C. ; Thomas, E. K. ; Flores-Romo, L. ; Xie, O. S. ; Agusala, K. ; Sutaria, S. ; Sinha, I. ; Champlin, R. E. ; Claxton, David. / Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. In: Blood. 1999 ; Vol. 93, No. 3. pp. 780-786.
@article{b8fd25eeac0f4303b12f0aef7f47dee9,
title = "Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses",
abstract = "We have previously reported that leukemic dendritic cells (DC) can be generated ex vivo from myelomonocytic precursors in chronic myelogenous leukemia. In this study we report the generation of DC from acute mye1ogenous leukemia (AML) cells and their potent ability to stimulate leukemia-specific cytolytic activity in autologous lymphocytes. DC were generated in vitro using granulocyte-macrophage colony-stimulating factor+interleukin-4 in combination with either tumor necrosis factor-α or CD40 ligand (CD40L). Cells from 19 AML patients with a variety of chromosomal abnormalities were studied for their ability to generate DC. In all but 1 case, cells with the morphology, phenotypic characteristics, and T-cell stimulatory properties of DC could be generated. These cells expressed high levels of major histocompatibility complex class I and class II antigens as well as the costimulatory molecules B7-2 and ICAM-1. In three cases these cells were determined to be of leukemic origin by fluorescence in situ hybridization for chromosomal abnormalities or Western blotting for the inv(16) fusion gene product. Autologous lymphocytes cocultured with AML-derived DC (DC-AL) were able to lyse autologous leukemia targets, whereas little cytotoxicity was noted against autologous, normal cells obtained from the patients during remission. We conclude that leukemia derived DC may be useful for immunotherapy of many AML patients.",
author = "A. Choudhury and Liang, {J. C.} and Thomas, {E. K.} and L. Flores-Romo and Xie, {O. S.} and K. Agusala and S. Sutaria and I. Sinha and Champlin, {R. E.} and David Claxton",
year = "1999",
month = "2",
day = "1",
language = "English (US)",
volume = "93",
pages = "780--786",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

Choudhury, A, Liang, JC, Thomas, EK, Flores-Romo, L, Xie, OS, Agusala, K, Sutaria, S, Sinha, I, Champlin, RE & Claxton, D 1999, 'Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses', Blood, vol. 93, no. 3, pp. 780-786.

Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. / Choudhury, A.; Liang, J. C.; Thomas, E. K.; Flores-Romo, L.; Xie, O. S.; Agusala, K.; Sutaria, S.; Sinha, I.; Champlin, R. E.; Claxton, David.

In: Blood, Vol. 93, No. 3, 01.02.1999, p. 780-786.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses

AU - Choudhury, A.

AU - Liang, J. C.

AU - Thomas, E. K.

AU - Flores-Romo, L.

AU - Xie, O. S.

AU - Agusala, K.

AU - Sutaria, S.

AU - Sinha, I.

AU - Champlin, R. E.

AU - Claxton, David

PY - 1999/2/1

Y1 - 1999/2/1

N2 - We have previously reported that leukemic dendritic cells (DC) can be generated ex vivo from myelomonocytic precursors in chronic myelogenous leukemia. In this study we report the generation of DC from acute mye1ogenous leukemia (AML) cells and their potent ability to stimulate leukemia-specific cytolytic activity in autologous lymphocytes. DC were generated in vitro using granulocyte-macrophage colony-stimulating factor+interleukin-4 in combination with either tumor necrosis factor-α or CD40 ligand (CD40L). Cells from 19 AML patients with a variety of chromosomal abnormalities were studied for their ability to generate DC. In all but 1 case, cells with the morphology, phenotypic characteristics, and T-cell stimulatory properties of DC could be generated. These cells expressed high levels of major histocompatibility complex class I and class II antigens as well as the costimulatory molecules B7-2 and ICAM-1. In three cases these cells were determined to be of leukemic origin by fluorescence in situ hybridization for chromosomal abnormalities or Western blotting for the inv(16) fusion gene product. Autologous lymphocytes cocultured with AML-derived DC (DC-AL) were able to lyse autologous leukemia targets, whereas little cytotoxicity was noted against autologous, normal cells obtained from the patients during remission. We conclude that leukemia derived DC may be useful for immunotherapy of many AML patients.

AB - We have previously reported that leukemic dendritic cells (DC) can be generated ex vivo from myelomonocytic precursors in chronic myelogenous leukemia. In this study we report the generation of DC from acute mye1ogenous leukemia (AML) cells and their potent ability to stimulate leukemia-specific cytolytic activity in autologous lymphocytes. DC were generated in vitro using granulocyte-macrophage colony-stimulating factor+interleukin-4 in combination with either tumor necrosis factor-α or CD40 ligand (CD40L). Cells from 19 AML patients with a variety of chromosomal abnormalities were studied for their ability to generate DC. In all but 1 case, cells with the morphology, phenotypic characteristics, and T-cell stimulatory properties of DC could be generated. These cells expressed high levels of major histocompatibility complex class I and class II antigens as well as the costimulatory molecules B7-2 and ICAM-1. In three cases these cells were determined to be of leukemic origin by fluorescence in situ hybridization for chromosomal abnormalities or Western blotting for the inv(16) fusion gene product. Autologous lymphocytes cocultured with AML-derived DC (DC-AL) were able to lyse autologous leukemia targets, whereas little cytotoxicity was noted against autologous, normal cells obtained from the patients during remission. We conclude that leukemia derived DC may be useful for immunotherapy of many AML patients.

UR - http://www.scopus.com/inward/record.url?scp=0032950187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032950187&partnerID=8YFLogxK

M3 - Article

C2 - 9920826

AN - SCOPUS:0032950187

VL - 93

SP - 780

EP - 786

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -

Choudhury A, Liang JC, Thomas EK, Flores-Romo L, Xie OS, Agusala K et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999 Feb 1;93(3):780-786.